Biodesix Partners With Vanderbilt to Develop Lung Cancer Risk Test Combining Blood Tests and Imaging
Biodesix and Vanderbilt are developing an AI-driven lung cancer risk test combining blood-based and imaging biomarkers.
New Griffith University research shows that electronic nose and gas chromatography-mass spectrometry analysis of exhaled ...
Biodesix, Inc. announced the addition of Digital Diagnostics to its Lung Diagnostics strategy, establishing the foundation for a multimodal diagnostic platform that combines blood-based biomarkers, ...
Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for ...
A pilot study suggests that letermovir may help prevent cytomegalovirus after lung transplant in participants with idiopathic ...
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit ...
Office-based pulmonary function testing, also known as spirometry, is a powerful tool for primary care physicians to diagnose and manage respiratory problems. An obstructive defect is indicated by a ...
A study of 471 patients found that the CALLY index, calculated from routine admission blood tests, outperformed established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results